Table of contents
This is a summary of the European public assessment report (EPAR) for Equioxx.It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Equioxx.
For practical information about using Equioxx, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Equioxx : EPAR - Summary for the public (PDF/78.6 KB)
First published: 30/06/2008
Last updated: 06/03/2017
|Agency product number||
|International non-proprietary name (INN) or common name||
|Anatomical therapeutic chemical veterinary (ATCvet) codes||
|Date of issue of marketing authorisation valid throughout the European Union||
42-46 rue Mederic
20/01/2022 Equioxx - EMEA/V/C/000142 - IAIN-0029-G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Anti-inflammatory and anti-rheumatic products, non-steroids
Alleviation of pain and inflammation associated with osteoarthritis and reduction of associated lameness in horses.
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 16-17 February 202119/02/2021